Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study

dc.creatorPescarini, Julia M.
dc.creatorCardoso, Andrey Moreira
dc.creatorSantos, Ricardo Ventura
dc.creatorScaff, Priscila
dc.creatorPaixao, Enny S.
dc.creatorRanzani, Otavio T.
dc.creatorSilva, Thiago Cerqueira
dc.creatorBoaventura, Viviane S.
dc.creatorBertoldo Junior, Juracy
dc.creatorOliveira, Vinicius de A.
dc.creatorWerneck, Guilherme L.
dc.creatorBarreto, Mauricio L.
dc.creatorBarral Netto, Manoel
dc.date2023-03-27T14:08:27Z
dc.date2023-03-27T14:08:27Z
dc.date2022
dc.date.accessioned2023-09-27T00:04:38Z
dc.date.available2023-09-27T00:04:38Z
dc.identifierPESCARINI, Julia M. et al. Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study. The Lancet, p. 1-19, 2022.
dc.identifier0140-6736
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/57588
dc.identifier10.2139/ssrn.4224510
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8897192
dc.descriptionBackground: We estimated the coverage and effectiveness of Covid-19 vaccines against laboratory-confirmed Covid-19 cases among indigenous people in Brazil. Methods: We linked nationwide immunization data with symptomatic and Severe Acute Respiratory Infection records and studied a cohort of vaccinated indigenous people aged ≥5 years between 18th Jan 2021 and 1st Mar 2022. We estimated the Covid-19 vaccination coverage and used Poisson regression to calculate the vaccine effectiveness (VE) of CoronaVac, ChAdOx1, and BNT162b2 against Covid-19 laboratory-confirmed symptomatic and severe cases (i.e., mortality, hospitalisation, and hospital-progression to Intensive Care Unit (ICU) or death). VE was estimated as (1-RR)*100, comparing unexposed (<14 days after the 1st dose), to partially (≥14 days after 1st dose to <14 days after 2nd dose), or fully vaccinated (≥14 days after 2nd dose). Findings: By 1st Mar 2022, 48·7% (35·0-62·3) of eligible indigenous people vs 74·8% (57·9-91·8) overall Brazilians had been fully vaccinated for Covid-19. Among the 370,092 indigenous subjects studied, we detected 1951 Covid-19 cases, of which 105 were hospitalised and 35 died. VE for the three Covid-19 vaccines combined was 53% (95%CI:44-60%) for symptomatic cases, 53% (95%CI:-56-86%) for mortality and 41% (95%CI:-35-75%) for hospitalisation. Among hospitalised patients, VE was 87% (95%CI:27-98%) for progression to ICU and 96% (95%CI: 90-99%) for death. Interpretation: Lower coverage but similar Covid-19 vaccine effectiveness among indigenous people than overall Brazilians suggest the need to expand access, timely vaccination, especially among children and adolescents, and urgently offer booster doses to achieve a great level of protection among this group.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsopen access
dc.subjectCOVID-19
dc.subjectPandemia
dc.subjectEficácia da vacina
dc.subjectCobertura vacinal
dc.subjectEstudo de coorte
dc.subjectPessoas indígenas
dc.subjectServiços de saúde
dc.subjectPopulação indígena
dc.subjectSaúde dos indígenas
dc.subjectAmeríndios
dc.subjectíndios
dc.subjectSul Americano
dc.subjectGrupos vulneráveis
dc.subjectTransmissão de doenças infecciosas
dc.subjectBrasil
dc.subjectCOVID-19
dc.subjectPandemic
dc.subjectVaccine effectiveness
dc.subjectVaccine coverage
dc.subjectCohort study
dc.subjectIndigenous peoples
dc.subjectHealth services
dc.subjectIndigenous population
dc.subjectHealth of indigenous people
dc.subjectAmerinds
dc.subjectIndians
dc.subjectSouth American
dc.subjectVulnerable groups
dc.subjectInfectious disease transmission
dc.subjectBrazil
dc.titleVaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study
dc.typePreprint


Este ítem pertenece a la siguiente institución